The HPV vaccine: An analysis of the FUTURE II study

Canadian Family Physician

Volumn 53, Issue 12, 2007, Pages 2157-2159

  Howard, Michelle ^a   Lytwyn, Alice ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ADOLESCENT; ADULT; CANCER SCREENING; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENERAL PRACTITIONER; GYNECOLOGICAL EXAMINATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SEXUALLY TRANSMITTED DISEASE; SHORT SURVEY; SINGLE BLIND PROCEDURE; STIGMA; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; WART VIRUS;

EID: 38849106724     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (13)

1. Pitts M, Clarke T. Human papillomavirus infections and risks of cervical cancer: what do women know? Health Educ Res 2002;17(6):706-14.
2. Zimet GD. Improving adolescent health: focus on HPV vaccine acceptance. J Adolesc Health 2005;37(6 Suppl):S17-23.
3. Dempsey AF, Zimet GD, Davis RL, Koutsky L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics 2006;117(5):1486-93.
4. Slomovitz BM, Sun CC, Frumovitz M, Soliman PT, Schmeler KM, Pearson HC, et al. Are women ready for the HPV vaccine? Gynecol Oncol 2006;103(1):151-4. Epub 2006 March 21.
5. Zimet GD, Mays RM, Fortenberry JD. Vaccines against sexually transmitted infections: promise and problems of the magic bullets for prevention and control. Sex Transm Dis 2000;27(1):49-52.
6. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Eng J Med 2007;356(19):1915-27.
7. Oxman AD, Guyatt GH. A consumer's guide to sub-group analyses. Ann Intern Med 1992;116(1):78-84.
8. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6(5):271-8.
9. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995;87(11):796-802.
10. Chaves SS, Garguillo P, Zhang JX, Civen R, Guris D, Mascola L, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med 2007;356(11):1121-9.
11. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327(18):1272-8.
12. Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999;91(3):252-8.
13. Boyce W, Doherty M, Fortin C, MacKinnon D. Canadian Youth, Sexual Health and HIV/AIDS Study: factors influencing knowledge, attitudes and behaviours. Toronto, ON: Council of Ministers of Education, Canada; 2003. Available from: http://www.cmec.ca/publications/aids/CYSHHAS_2002_EN.pdf. Accessed 2007 November 7.